TY - JOUR T1 - Macroscopic and Microscopic Activation of <em>α</em>7 Nicotinic Acetylcholine Receptors by the Structurally Unrelated Allosteric Agonist-Positive Allosteric Modulators (ago-PAMs) B-973B and GAT107 JF - Molecular Pharmacology JO - Mol Pharmacol SP - 43 LP - 61 DO - 10.1124/mol.118.113340 VL - 95 IS - 1 AU - Marta Quadri AU - Sumanta Garai AU - Ganesh A. Thakur AU - Clare Stokes AU - Alican Gulsevin AU - Nicole A. Horenstein AU - Roger L. Papke Y1 - 2019/01/01 UR - http://molpharm.aspetjournals.org/content/95/1/43.abstract N2 - B-973 is an efficacious type II positive allosteric modulator (PAM) of α7 nicotinic acetylcholine receptors that, like 4BP-TQS and its active isomer GAT107, can produce direct allosteric activation in addition to potentiation of orthosteric agonist activity, which identifies it as an allosteric activating (ago)-PAM. We compared the properties of B-973B, the active enantiomer of B-973, with those of GAT107 regarding the separation of allosteric potentiation and activation. Both ago-PAMs can strongly activate mutants of α7 that are insensitive to standard orthosteric agonists like acetylcholine. Likewise, the activity of both ago-PAMs is largely eliminated by the M254L mutation in the putative transmembrane PAM-binding site. Allosteric activation by B-973B appeared more protracted than that produced by GAT107, and B-973B responses were relatively insensitive to the noncompetitive antagonist mecamylamine compared with GAT107 responses. Similar differences are also seen in the single-channel currents. The two agents generate unique profiles of full-conductance and subconductance states, with B-973B producing protracted bursts, even in the presence of mecamylamine. Modeling and docking studies suggest that the molecular basis for these effects depends on specific interactions in both the extracellular and transmembrane domains of the receptor. ER -